Clinical Trials Logo

Clinical Trial Summary

Hepatic encephalopathy is a serious complication of cirrhosis which relays under the burden of diseases with therapeutical difficulties for its given morbidity and mortality and the high recurrence it poses. Its treatment remains a challenge for most of the cases. Even more, minimal hepatic encephalopathy is an entity that has an additional morbidity for it being a subclinical entity. As so, the investigators propose an auxiliary treatment for the management of such patients with minimal hepatic encephalopathy, using a specific diet consisting on hyperproteic and fibre-rich foods along with two independent interventions, whether a probiotic, lactobacillus reuteri, or a drug, nitozoxanide, so to diminish the rate of progression to any clinical stage of hepatic encephalopathy and to revert minimal hepatic encephalopathy itself to none hepatic encephalopathy.


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01135628
Study type Interventional
Source Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Contact
Status Completed
Phase N/A
Start date August 2010
Completion date July 2014

See also
  Status Clinical Trial Phase
Completed NCT01349348 - Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites Phase 3
Active, not recruiting NCT04682847 - Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
Recruiting NCT05904470 - A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Phase 2
Completed NCT02138253 - A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV Phase 2
Recruiting NCT02652351 - Human Umbilical Cord-Mesenchymal Stem Cells for Hepatic Cirrhosis Phase 1
Completed NCT00794482 - Multi-national Cirrhosis Study to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity. Phase 3
Completed NCT00856713 - Clearance of NRL972 in Patients With Cirrhosis and in Healthy Volunteers Phase 1
Completed NCT02163512 - Effect of Beta-adrenergic Blockers on Cardiac Function, Systemic and Splanchnic Haemodynamic and Kidney Function in Cirrhotic Patiets With Refractory Ascites
Completed NCT00857480 - Evaluation of the PK of NRL972 Following Pre- and co-Administration of Ursodeoxycholic Acid and Cloxacillin Phase 1
Completed NCT00006164 - Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment Phase 3
Completed NCT03486912 - A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis Phase 2
Completed NCT00698464 - Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function Phase 1
Completed NCT02778425 - The Treatment of Hepatocirrhosis and Portal Hypertension N/A
Completed NCT03420768 - A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C Phase 2
Completed NCT03445208 - A Study of Experimental Medication BMS-986036 Given to Healthy Participants Phase 1
Completed NCT03804593 - HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)
Completed NCT03712280 - MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy) Phase 2
Completed NCT02230683 - A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension Phase 2
Completed NCT02230670 - A Study of IDN-6556 in Subjects With Liver Cirrhosis Phase 2
Completed NCT00856869 - Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers Phase 1/Phase 2